Suppr超能文献

成本中性支付方环境下质子束治疗的患者优先级排序:利用临床获益评分进行资源分配

Patient Prioritization for Proton Beam Therapy in a Cost-neutral Payer Environment: Use of the Clinical Benefit Score for Resource Allocation.

作者信息

Sharma Ankur M, Khairnar Rahul, Kowalski Emily S, Remick Jill, Nichols Elizabeth M, Mohindra Pranshu, Yock Torunn, Regine William, Mishra Mark V

机构信息

Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA.

Pharmaceutical Health Services Research, University of Maryland, Baltimore, USA.

出版信息

Cureus. 2019 Sep 19;11(9):e5703. doi: 10.7759/cureus.5703.

Abstract

Objectives There has been a rapid increase in the number of one- and two-room proton beam therapy (PBT) centers, which may be limited in the number of patients they can treat. The objective of this study was to analyze the impact of the 'clinical benefit score' (CBS), utilized as a method for treatment prioritization for PBT operating in a 'cost-neutral' proton-photon payer environment. Materials & methods This study includes patients considered for PBT at a center that initially had only one or two treatment rooms available for clinical use. Patients were prospectively scored using the CBS, and higher scores were prioritized. The outcome was receipt of PBT and the independent variable was CBS. Crude and adjusted analyses were performed using logistic regression. Results There were 2163 patients evaluated. A total of 205 patients (9.5%) were deemed candidates for PBT, which was received by 122 (5.6%) patients. In patients considered for PBT, the mean CBS was 18.7. Patients who were <21 years old, female, non-Caucasian, receiving re-irradiation, and those with Medicare had a higher CBS. Multivariate analysis adjusting for insurance status revealed both CBS and insurance to be significant predictors for receiving PBT. A unit increase in CBS was associated with 1.04 times increased odds of receiving PBT (OR=1.04, 95%CI: 1.01-1.07, p=0.0145) and having Medicare was associated with 3.13 times increased odds of receiving PBT (OR=3.13, 95%CI: 1.57-6.26, p=0.0012). Subgroup analysis, which only included patients enrolled prior to opening the second gantry, showed 1.05 times increased odds of receiving PBT per unit increase in CBS (OR=1.05, 95%CI: 1.00-1.10, p=0.03) and 2.87 times increased odds of receiving PBT in patients with Medicare (OR=2.87, 95%CI: 1.04-7.92, p=0.04). Conclusion  The CBS utilized was significantly associated with the receipt of PBT in a cost-neutral payer setting. Physicians may consider the use of CBS as a resource allocation tool.

摘要

目的 单室和双室质子束治疗(PBT)中心的数量迅速增加,但其可治疗的患者数量可能有限。本研究的目的是分析 “临床获益评分”(CBS)在 “成本中性” 的质子 - 光子支付环境下作为PBT治疗优先级确定方法的影响。材料与方法 本研究纳入了一家最初仅有一两个临床可用治疗室的中心考虑接受PBT治疗的患者。使用CBS对患者进行前瞻性评分,分数越高优先级越高。结局指标是是否接受PBT,自变量是CBS。采用逻辑回归进行粗分析和校正分析。结果 共评估了2163例患者。共有205例患者(9.5%)被认为是PBT的候选者,其中122例(5.6%)患者接受了PBT。在考虑接受PBT的患者中,CBS的平均值为18.7。年龄<21岁、女性、非白种人、接受再照射以及有医疗保险的患者CBS较高。调整保险状态后的多因素分析显示,CBS和保险都是接受PBT的显著预测因素。CBS每增加一个单位,接受PBT的几率增加1.04倍(OR = 1.04,95%CI:1.01 - 1.07,p = 0.0145),有医疗保险的患者接受PBT的几率增加3.13倍(OR = 3.13,95%CI:1.57 - 6.26,p = 0.0012)。仅纳入第二个机架启用前入组患者的亚组分析显示,如果CBS每增加一个单位,接受PBT的几率增加1.05倍(OR = 1.05,95%CI:1.00 - 1.10,p = 0.03),有医疗保险的患者接受PBT的几率增加2.87倍(OR = 2.87,95%CI:1.04 - 7.92,p = 0.04)。结论 在成本中性的支付环境下,所使用的CBS与接受PBT显著相关。医生可考虑将CBS用作资源分配工具。

相似文献

2
Ethical Allocation of Proton Therapy and the Insurance Review Process.
Pract Radiat Oncol. 2021 Sep-Oct;11(5):e449-e458. doi: 10.1016/j.prro.2021.01.007. Epub 2021 Feb 3.
3
Differences in Patterns of Care and Referral Between Proton and Photon Therapy.
Int J Part Ther. 2024 Apr 22;11:100005. doi: 10.1016/j.ijpt.2023.10.001. eCollection 2024 Mar.
4
Patterns of Proton Beam Therapy Use in Clinical Practice between 2007 and 2019 in Korea.
Cancer Res Treat. 2021 Oct;53(4):935-943. doi: 10.4143/crt.2021.409. Epub 2021 May 17.
5
Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018.
JAMA Netw Open. 2022 Apr 1;5(4):e228970. doi: 10.1001/jamanetworkopen.2022.8970.
6
A population-based assessment of proton beam therapy utilization in California.
Am J Manag Care. 2020 Feb 1;26(2):e28-e35. doi: 10.37765/ajmc.2020.42398.
9
Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy.
Clin Genitourin Cancer. 2021 Jun;19(3):255-266.e7. doi: 10.1016/j.clgc.2020.08.009. Epub 2020 Aug 28.

引用本文的文献

1
Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018.
JAMA Netw Open. 2022 Apr 1;5(4):e228970. doi: 10.1001/jamanetworkopen.2022.8970.

本文引用的文献

3
Proton beam therapy for cancer in the era of precision medicine.
J Hematol Oncol. 2018 Dec 12;11(1):136. doi: 10.1186/s13045-018-0683-4.
4
Proton beam therapy in pediatric oncology.
Curr Opin Pediatr. 2019 Feb;31(1):28-34. doi: 10.1097/MOP.0000000000000724.
8
Principles and reality of proton therapy treatment allocation.
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):499-508. doi: 10.1016/j.ijrobp.2014.03.023. Epub 2014 May 3.
10
Reference pricing with evidence development: a way forward for proton therapy.
J Clin Oncol. 2014 May 20;32(15):1540-2. doi: 10.1200/JCO.2014.55.6613. Epub 2014 Apr 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验